For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit: www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Must have been diagnosed with either Stage IIIA (> 1 mm tumor in lymph node)/B/C/D or
             Stage IV melanoma by American Joint Committee on Cancer (AJCC) v8 and have
             histologically confirmed melanoma that is completely surgically resected (free of
             disease) with negative margins in order to be eligible

          -  Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of ≤ 1

          -  Complete resection must be performed within 12 weeks prior to randomization

          -  All participants must have disease-free status documented by a complete physical
             examination within 14 days prior to randomization and imaging studies within 35 days
             prior to randomization

          -  Tumor tissue must be provided for biomarker analyses

        Exclusion Criteria:

          -  History of uveal melanoma

          -  Untreated/unresected CNS metastases or leptomeningeal metastases

          -  Active, known, or suspected autoimmune disease

          -  Participants with serious or uncontrolled medical disorder

          -  Prior immunotherapy treatment for any prior malignancy: No prior immunotherapies are
             permitted

          -  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 4 weeks prior
             to screening

        Other protocol-defined inclusion/exclusion criteria apply